AJP - Heart AJP: Gastrointestinal and Liver Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol 287: H2891-H2898, 2004. First published June 3, 2004; doi:10.1152/ajpheart.01051.2003
0363-6135/04 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
287/6/H2891    most recent
01051.2003v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schreiner, K. D.
Right arrow Articles by Schoels, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schreiner, K. D.
Right arrow Articles by Schoels, W.

Biventricular hypertrophy in dogs with chronic AV block: effects of cyclosporin A on morphology and electrophysiology

Kirsten D. Schreiner,* Kamilla Kelemen,* Joerg Zehelein, Ruediger Becker, Julia C. Senges, Alexander Bauer, Frederik Voss, Patrizia Kraft, Hugo A. Katus, and Wolfgang Schoels

Department of Cardiology, University of Heidelberg, 69115 Heidelberg, Germany

Submitted 5 November 2003 ; accepted in final form 10 May 2004

Chronic atrioventricular (AV) block (CAVB) and biventricular hypertrophy in dogs increase susceptibility to drug-induced polymorphic ventricular tachycardia (PVT). In various rodent models, cyclosporin A (CsA) prevented hypertrophy. A similar effect in the CAVB model would allow us to determine whether hypertrophy represents an epiphenomenon, the cause of electrophysiological changes, and/or the anatomic substrate for PVTs. Upon AV node ablation, 6 dogs were studied acutely (AAVB), 25 dogs were kept for 6 (6W) and 12 wk (12W), receiving no treatment [CTL-CAVB-6W (n = 6) and CTL-CAVB-12W (n = 7)] or a daily oral dose of 10–20 mg/kg CsA directly (n = 6, CsA-CAVB-6W) or 6 wk after radio-frequency ablation (n = 6, CsA-CAVB-12W). For the final study, dogs were anesthetized, and 60 needles were inserted into both ventricles and connected to a multiplexer mapping system. Local effective refractory periods (ERPs) were determined at 56 ± 22 randomly selected sites (extrastimulus technique, basic cycle length = 800 ms). Arrhythmias within 30 min after application of almokalant (0.34 µmol/kg iv) were registered. The hearts were then excised to obtain the heart weight-body weight index (HBWI). Compared with AAVB, CTL-CAVB-6W and CTL-CAVB-12W showed increased HBWI and ERP associated with PVT inducibility in none of six AAVB dogs, four of six CTL-CAVB-6W dogs, and one of seven CTL-CAVB-12W dogs. Compared with CTL-CAVB-6W and CTL-CAVB-12W, CsA-CAVB-6W and CsA-CAVB-12W partially prevented hypertrophy or led to a regression of hypertrophy without reducing ERP prolongation. Despite ERP prolongation, PVTs were no longer inducible with CsA treatment. Thus prolongation of refractoriness seems to provide the trigger, but hypertrophy provides the essential substrate for the induction of PVTs in this model.

regression of hypertrophy; mapping; torsade de pointes



Address for reprint requests and other correspondence: K. Kelemen, Dept. of Cardiology, Univ. of Heidelberg, Bergheimerstr. 58, 69115 Heidelberg, Germany (E-mail: kamilla_kelemen{at}med.uni-heidelberg.de)




This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
S. K.G. Winckels, M. B. Thomsen, P. Oosterhoff, A. Oros, J. D.M. Beekman, N. J.M. Attevelt, L. Kretzers, and M. A. Vos
High-Septal Pacing Reduces Ventricular Electrical Remodeling and Proarrhythmia in Chronic Atrioventricular Block Dogs
J. Am. Coll. Cardiol., August 28, 2007; 50(9): 906 - 913.
[Abstract] [Full Text] [PDF]


Home page
Toxicol PatholHome page
Y. J. Kang
Cardiac Hypertrophy: A Risk Factor for QT-Prolongation and Cardiac Sudden Death
Toxicol Pathol, January 1, 2006; 34(1): 58 - 66.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2004 by the American Physiological Society.